CytRx Corporation's Molecular Chaperone Drug Discovery Platform to Be Published in the Peer-Reviewed Journal of Biomolecular Screening

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics based on molecular chaperone regulation, today announced that research conducted at its San Diego laboratory to develop its proprietary Master Chaperone Regulator Assay (MaCRA) for compound screening has been accepted for publication in the November 2008 issue of the peer-reviewed Journal of Biomolecular Screening.

Back to news